Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Business Wire (Jan 22, 2013)
-
-
-
PR Newswire (Jan 2, 2013)
-
-
Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short CoveringKapitall • Fri, Nov 30, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short CoveringKapitall • Fri, Nov 30, 2012
-
-
-
5 Fast Growing Healthcare Stocks That Analysts LikeZetaKap • Thu, Aug 30, 2012 -
-
-
7 High-Growth Small-Cap Stocks With Strong Buy RatingsZetaKap • Sat, Jul 28, 2012
-
Thursday Options RecapFrederic Ruffy • Thu, Jul 12, 2012
There are no Transcripts on MAPP.
-
at Fox Business (Jan 23, 2013)
-
Business Wire (Jan 22, 2013)
-
PR Newswire (Jan 2, 2013)
-
at MarketWatch.com (Nov 23, 2012)
-
at CNBC.com (Nov 23, 2012)
-
PR Newswire (Nov 21, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Nov 1, 2012)
-
MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine DrugPR Newswire (Oct 16, 2012)
-
at MarketWatch.com (Aug 30, 2012)
-
PR Newswire (Aug 9, 2012)
-
PR Newswire (Aug 1, 2012)
-
PR Newswire (Jul 31, 2012)
-
PR Newswire (Jul 24, 2012)
-
PR Newswire (May 4, 2012)
-
PR Newswire (May 1, 2012)
MAPP vs. ETF Alternatives
Company Description
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the potential acute treatment of migraine. The U.S. Food and... More
